Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

PURPOSE: HER2-targeted therapies have substantially improved the outcome of patients with breast cancer, however, they can be associated with cardiac toxicity. Guidelines recommend holding HER2-targeted therapies until resolution of cardiac dysfunction. SAFE-HEaRt is the first trial that prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynce, F., Barac, A., Geng, X., Dang, C., Yu, A. F., Smith, K. L., Gallagher, C., Pohlmann, P. R., Nunes, R., Herbolsheimer, P., Warren, R., Srichai, M. B., Hofmeyer, M., Cunningham, A., Timothee, P., Asch, F. M., Shajahan-Haq, A., Tan, M. T., Isaacs, C., Swain, S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534513/
https://www.ncbi.nlm.nih.gov/pubmed/30852761
http://dx.doi.org/10.1007/s10549-019-05191-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534513/
https://www.ncbi.nlm.nih.gov/pubmed/30852761
http://dx.doi.org/10.1007/s10549-019-05191-2

Ejemplares similares